Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.

Ryota ShibakiDaichi FujimotoEisaku MiyauchiYoko TsukitaIchiro NakachiDaisuke AraiYoshihiko SakataNaoki ShinguToshio ShimokawaTakashi KijimaMotohiro TamiyaSachiko KawanaSatoshi HaraGo SaitoYuki SatoToshihide YokoyamaShinya SakataYoshihiko TaniguchiAkito HataHirotaka MatsumotoTeppei YamaguchiNobuyuki Yamamoto

Published in: Lung cancer (Amsterdam, Netherlands) (2024)

Chemoimmunotherapy is a feasible treatment approach for patients with ES-SCLC and mild IIP.

Keyphrases

interstitial lung disease
phase iii
open label
small cell lung cancer
systemic sclerosis
phase ii
clinical trial
study protocol
phase ii study
rheumatoid arthritis
idiopathic pulmonary fibrosis
randomized controlled trial
brain metastases
combination therapy
placebo controlled
rectal cancer